THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Company limited by guarantee

Company Registration Number:
14261409 (England and Wales)

Unaudited statutory accounts for the year ended 31 July 2025

Period of accounts

Start date: 1 August 2024

End date: 31 July 2025

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Contents of the Financial Statements

for the Period Ended 31 July 2025

Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Profit And Loss Account

for the Period Ended 31 July 2025

2025 2024


£

£
Turnover: 10,000 25,000
Cost of sales: 0 0
Gross profit(or loss): 10,000 25,000
Distribution costs: 0 0
Administrative expenses: ( 10,000 ) ( 25,000 )
Other operating income: 0 0
Operating profit(or loss): 0 0
Interest receivable and similar income: 0 0
Interest payable and similar charges: 0 0
Profit(or loss) before tax: 0 0
Tax: 0 0
Profit(or loss) for the financial year: 0 0

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Balance sheet

As at 31 July 2025

Notes 2025 2024


£

£
Fixed assets
Intangible assets:   0 0
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 0 0
Current assets
Stocks:   0 0
Debtors:   0 0
Cash at bank and in hand: 2,341 0
Investments:   0 0
Total current assets: 2,341 0
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year: 3 ( 2,341 ) 0
Net current assets (liabilities): 0 0
Total assets less current liabilities: 0 0
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Accruals and deferred income: 0 0
Total net assets (liabilities): 0 0
Members' funds
Profit and loss account: 0 0
Total members' funds: 0 0

The notes form part of these financial statements

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Balance sheet statements

For the year ending 31 July 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 29 April 2026
and signed on behalf of the board by:

Name: Diana Natalie Busari
Status: Director

The notes form part of these financial statements

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Notes to the Financial Statements

for the Period Ended 31 July 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Valuation information and policy

    The financial statements have been prepared under the historical cost convention. Cash and cash equivalents are valued at the amounts held. Income and expenditure are recognised at the transaction value. The company has no complex financial instruments or assets requiring revaluation.

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Notes to the Financial Statements

for the Period Ended 31 July 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 0 0

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Notes to the Financial Statements

for the Period Ended 31 July 2025

3. Creditors: amounts falling due within one year note

2025 2024
£ £
Bank loans and overdrafts 0 0
Amounts due under finance leases and hire purchase contracts 0 0
Trade creditors 0 0
Taxation and social security 0 0
Accruals and deferred income 2,341 0
Other creditors 0 0
Total 2,341 0

COMMUNITY INTEREST ANNUAL REPORT

THE NERVE OF MY MULTIPLE SCLEROSIS CIC

Company Number: 14261409 (England and Wales)

Year Ending: 31 July 2025

Company activities and impact

The Nerve of My Multiple Sclerosis CIC supports and advocates for Black people living with neurological autoimmune conditions, including Multiple Sclerosis, NMOSD and MOGAD, with a particular focus on Black women and Black girls. During the financial year, the organisation delivered community-based support activities in the United Kingdom. These included in-person events designed to provide safe, culturally relevant spaces where individuals could access information, share lived experiences, and build peer support networks. As demand increased, the organisation extended the duration of its events to improve accessibility for attendees travelling from different parts of the UK. The organisation also expanded its reach beyond the UK through its affiliated branches in Ghana and Nigeria. These branches supported community engagement and awareness activities, helping to address gaps in knowledge, stigma, and access to information about neurological conditions in Black communities. In addition, the organisation carried out community engagement and survey work to better understand the experiences of Black individuals living with these conditions. This work identified ongoing challenges, including delays in diagnosis, lack of culturally appropriate care, and underrepresentation in research. As a result, the organisation began developing its research and advocacy work, including building partnerships and exploring initiatives to improve representation and outcomes for Black communities affected by neurological conditions. Overall, the company’s activities during the financial year have contributed to increased awareness, strengthened peer support, and improved community understanding of neurological autoimmune conditions within the populations it serves.

Consultation with stakeholders

The company regularly consults with its key stakeholders, including patients, community members, healthcare professionals, and partner organisations. Consultation takes place through community events, direct engagement, and surveys designed to understand the experiences and needs of Black people living with neurological autoimmune conditions such as Multiple Sclerosis, NMOSD and MOGAD. Feedback from these consultations has directly informed the company’s activities. For example, increased demand for accessible and inclusive support led to the extension of community event formats to accommodate attendees travelling from different locations. Engagement with stakeholders also highlighted the need for greater awareness, culturally relevant information, and improved representation in research. In response, the company has expanded its activities to include international community engagement through its branches in Ghana and Nigeria, as well as developing its research and advocacy work to address identified gaps in care, awareness, and representation. The company will continue to use stakeholder feedback to shape its services and ensure that its activities remain responsive to the needs of the communities it serves.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
29 April 2026

And signed on behalf of the board by:
Name: Diana Natalie Busari
Status: Director